SE9804314D0 - New pharmaceutical formulation - Google Patents

New pharmaceutical formulation

Info

Publication number
SE9804314D0
SE9804314D0 SE9804314A SE9804314A SE9804314D0 SE 9804314 D0 SE9804314 D0 SE 9804314D0 SE 9804314 A SE9804314 A SE 9804314A SE 9804314 A SE9804314 A SE 9804314A SE 9804314 D0 SE9804314 D0 SE 9804314D0
Authority
SE
Sweden
Prior art keywords
dosage forms
blocking agent
calcium channel
channel blocking
pharmaceutical formulation
Prior art date
Application number
SE9804314A
Other languages
English (en)
Swedish (sv)
Inventor
Arne Eek
Lars Josefsson
Per Johan Lundberg
Aake Pilbrant
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9804314A priority Critical patent/SE9804314D0/xx
Publication of SE9804314D0 publication Critical patent/SE9804314D0/xx
Priority to KR1020017007344A priority patent/KR20010093822A/ko
Priority to CN99816118A priority patent/CN1334731A/zh
Priority to JP2000587768A priority patent/JP2002532425A/ja
Priority to BR9916224-5A priority patent/BR9916224A/pt
Priority to EP99963820A priority patent/EP1150677A1/en
Priority to PCT/SE1999/002315 priority patent/WO2000035448A1/en
Priority to IL14338699A priority patent/IL143386A0/xx
Priority to AU20186/00A priority patent/AU776079B2/en
Priority to CA002352613A priority patent/CA2352613A1/en
Priority to NZ511999A priority patent/NZ511999A/xx
Priority to ZA200104273A priority patent/ZA200104273B/en
Priority to NO20012915A priority patent/NO20012915L/no
Priority to HK02103023.3A priority patent/HK1041224A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9804314A 1998-12-14 1998-12-14 New pharmaceutical formulation SE9804314D0 (sv)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE9804314A SE9804314D0 (sv) 1998-12-14 1998-12-14 New pharmaceutical formulation
NZ511999A NZ511999A (en) 1998-12-14 1999-12-10 Pharmaceutical formulation comprising a H+,K+-ATPase inhibitor and a gastric antisecretory prostaglandin analogue
PCT/SE1999/002315 WO2000035448A1 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
CN99816118A CN1334731A (zh) 1998-12-14 1999-12-10 新的药用制剂
JP2000587768A JP2002532425A (ja) 1998-12-14 1999-12-10 新規な医薬製剤
BR9916224-5A BR9916224A (pt) 1998-12-14 1999-12-10 Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
EP99963820A EP1150677A1 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
KR1020017007344A KR20010093822A (ko) 1998-12-14 1999-12-10 신규한 제약 제형
IL14338699A IL143386A0 (en) 1998-12-14 1999-12-10 Pharmaceutical dosage form comprising a h+, k+ -atpase inhibitor and gastric antisecretory prostaglandin analogue compound
AU20186/00A AU776079B2 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
CA002352613A CA2352613A1 (en) 1998-12-14 1999-12-10 New pharmaceutical formulation
ZA200104273A ZA200104273B (en) 1998-12-14 2001-05-24 New pharmaceutical formulation.
NO20012915A NO20012915L (no) 1998-12-14 2001-06-13 Ny farmasöytisk formulering
HK02103023.3A HK1041224A1 (zh) 1998-12-14 2002-04-22 新的藥物製劑

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804314A SE9804314D0 (sv) 1998-12-14 1998-12-14 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
SE9804314D0 true SE9804314D0 (sv) 1998-12-14

Family

ID=20413648

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9804314A SE9804314D0 (sv) 1998-12-14 1998-12-14 New pharmaceutical formulation

Country Status (14)

Country Link
EP (1) EP1150677A1 (xx)
JP (1) JP2002532425A (xx)
KR (1) KR20010093822A (xx)
CN (1) CN1334731A (xx)
AU (1) AU776079B2 (xx)
BR (1) BR9916224A (xx)
CA (1) CA2352613A1 (xx)
HK (1) HK1041224A1 (xx)
IL (1) IL143386A0 (xx)
NO (1) NO20012915L (xx)
NZ (1) NZ511999A (xx)
SE (1) SE9804314D0 (xx)
WO (1) WO2000035448A1 (xx)
ZA (1) ZA200104273B (xx)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US8268333B2 (en) 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
US8980322B2 (en) 2003-03-17 2015-03-17 Takeda Pharmaceutical Company Limited Controlled release composition
EP1642593A1 (en) * 2003-06-06 2006-04-05 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2005289867A (ja) * 2004-03-31 2005-10-20 Lintec Corp 経口投与剤
CN1311824C (zh) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 奥美拉唑肠溶微粒制剂及制备方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2006234632B2 (en) * 2005-04-12 2011-10-27 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
EP1987820A1 (en) * 2007-05-04 2008-11-05 Christian Fiala, Ph. D. Slow release misoprostol for obstetric and/or gynaecological applications
CN102078615A (zh) * 2011-01-21 2011-06-01 北京华禧联合科技发展有限公司 质子泵抑制剂和胃黏膜保护剂组合物
JP2017522321A (ja) * 2014-07-17 2017-08-10 ダウ グローバル テクノロジーズ エルエルシー エチルセルロース分散系とフィルム
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CA3121746A1 (en) 2017-01-04 2018-07-12 Herriot TABUTEAU Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20230125826A (ko) 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
US12005118B2 (en) 2022-05-19 2024-06-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Also Published As

Publication number Publication date
NO20012915D0 (no) 2001-06-13
EP1150677A1 (en) 2001-11-07
WO2000035448A1 (en) 2000-06-22
HK1041224A1 (zh) 2002-07-05
ZA200104273B (en) 2002-08-26
KR20010093822A (ko) 2001-10-29
NO20012915L (no) 2001-08-13
BR9916224A (pt) 2001-09-04
AU776079B2 (en) 2004-08-26
NZ511999A (en) 2002-10-25
CA2352613A1 (en) 2000-06-22
AU2018600A (en) 2000-07-03
CN1334731A (zh) 2002-02-06
IL143386A0 (en) 2002-11-10
JP2002532425A (ja) 2002-10-02

Similar Documents

Publication Publication Date Title
SE9804314D0 (sv) New pharmaceutical formulation
BR9506029A (pt) Forma farmaêutica oral de múltipla dosagem unitária em tablete processo para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem para o tratamento de doenças inflamatórias gastrointestinais em maniferos e no homem e embalgem de ampola de pressão transversal
UA88523C2 (ru) Фармацевтический препарат рофлумиласта для местного применения
ATE359077T1 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
SE0100568D0 (sv) Compounds
HK1076605A1 (en) Formulations
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
IL157921A0 (en) Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
SE9901573D0 (sv) New compounds
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
HUP0302068A2 (hu) COX-2 inhibitorok alkalmazása immundeficienciával járó rendellenességek kezelésére vagy megelőzésére és ezeket tartalmazó gyógyszerkészítmények
RU2003125274A (ru) Применение флумазенила в производстве лекарства для лечения алкогольной зависимости
NO20005912L (no) Sulfonylsyre- eller sulfonylamino-N-(heteroaralkyl)- azaheterocyklylamidforbindelser
MXPA03009849A (es) Uso de azitromicina para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias no infecciosas.
EA200401097A1 (ru) Лекарственная форма с регулируемым высвобождением активного ингредиента
SE0100566D0 (sv) Compounds
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
MXPA04005902A (es) Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
SE9901572D0 (sv) New compounds
SE0201837D0 (sv) Chemical compounds
SE0101692D0 (sv) Compounds
ATE462419T1 (de) Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren